论文部分内容阅读
目的:对比观察非布司他和别嘌醇治疗痛风伴高尿酸血症的疗效和不良反应。方法:选择于我院诊治的患者72例,随机分为观察组和对照组,每组各36例,观察组给予口服非布司他,对照组口服别嘌醇,1月后比较两组血尿酸水平和不良反应发生率。结果:治疗后两组患者的血尿酸水平均显著下降至正常范围,与治疗前相比差异均具有统计学意义(P均<0.05);治疗后两组患者血尿酸水平相比,虽观察组患者略低,但经t检验,治疗后两组患者血尿酸水平比较无统计学意义(P>0.05);虽然观察组患者不良反应发生率低于对照组,但经卡方检验,两组不良反应发生率比较无统计学意义(P>0.05)。结论:非布司他能明显降低痛风伴高尿酸血症患者的尿酸水平,不良反应较低,值得临床应用。
Objective: To compare the efficacy and adverse reactions of febuxostat and allopurinol in treating gout with hyperuricemia. Methods: Seventy-two patients selected for diagnosis and treatment in our hospital were randomly divided into observation group and control group, with 36 cases in each group. The observation group was given oral febuxostat and the control group was given oral allopurinol. Uric acid levels and the incidence of adverse reactions. Results: After treatment, the levels of serum uric acid in both groups significantly decreased to the normal range, with statistical significance compared with those before treatment (all P <0.05). Although the level of serum uric acid in the two groups after treatment was significantly lower than that in the observation group The patients were slightly lower, but after t test, serum uric acid levels in the two groups were not statistically significant (P> 0.05). Although the incidence of adverse reactions in the observation group was lower than that in the control group, the two groups were poor The incidence of the reaction was not statistically significant (P> 0.05). Conclusion: Febu bovine can significantly reduce the level of uric acid in patients with gout and hyperuricemia with low adverse reactions, which is worthy of clinical application.